IQSTEL Reports Strong Revenue Growth, But Profitability and Acquisition Milestones Remain Key

What happened

IQSTEL reported preliminary H1 2026 revenue of $207 million, a 59% year-over-year increase, positioning the company for a half-billion-dollar annual run rate and an $8 million EBITDA run rate. However, the company's Q1 2026 results showed a gross margin of just 2.1% and an operating loss of nearly $1 million, underscoring that revenue scale has not translated into profitability. The company's path to sustained earnings hinges on closing the ULTRANET acquisition, which requires definitive agreements and regulatory approvals by early August 2026. Until such milestones are met, the company continues to rely on discounted equity financing, which dilutes existing shareholders. The updated revenue figures are positive, but they do not alter the fundamental risk profile that the DeepValue report highlighted.

Implication

The H1 revenue update reinforces top-line growth but does not change the core investment thesis: IQST remains a high-risk, high-reward speculation on execution rather than a fundamental compounder. The $207 million revenue run rate is encouraging, but the company needs to demonstrate that it can convert that scale into positive operating income and free cash flow. The key catalyst remains the ULTRANET acquisition, which promises to add $130 million in revenue and $4.5 million in net profit. However, the timeline is tight, and failure to close could trigger heavy equity-line usage and further dilution. A prudent approach is to wait for the definitive agreement and evidence of cash flow improvement before considering a position, with an attractive entry near $0.90 per the report.

Thesis delta

The preliminary H1 revenue is higher than anticipated, potentially lifting the base-case scenario slightly, but it does not resolve the central thesis tension between top-line growth and bottom-line losses. The DeepValue report's WAIT rating and attractive entry price remain valid, as the fundamental risks around profitability and dilution persist. The new data does not shift the probability-weighted outcome enough to change the recommended action.